Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in moderate to severe Sjogren's disease
ISRCTN14534389Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of nipocalimab in Sjögren's syndrome (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in ClinESSDAI score at Week 48. Started Mar 2025; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on ISRCTN14534389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14534389.